Diabetes can be managed effectively and controlled once it has been accurately diagnosed. The goal of diabetes management is to prevent short-and long-term complications of diabetes from developing.
Diabetic foot ulcer is a principal diabetic complication. Unfortunately, 84% of lower-limb amputations are an effect of so-called diabetic foot, chronic foot ulcers suffered by 15 to 20 percent of diabetes patients at some point in their lives. Ten to 25 percent of these patients will end up having some kind of amputation. It could be said that every 30 seconds, a diabetes patient of either sex is being amputated in a health center somewhere in the world. About 50 percent of these patients undergo a second amputation on their other lower limb. After a major amputation, fewer than 50 percent of amputees survive for more than five years.
HEBERPROT-P is a drug for stimulating and sustaining scar formation for chronic ulcers of all types on the lower extremities of diabetic patients
It's a new injectable medicine developed by eminent
Cuban scientists at the national Genetic Engineering and Biotechnology
Center (CIGB), together with highly qualified professionals of the
National Institute of Angiology and Vascular Surgery. Heberprot-P
is an innovative Cuban product containing recombinant human epidermal growth factor
for peri- and intra-lesional infiltration. Its therapeutic properties,
method of application and niche indications are unique internationally.
Evidence reveals it accelerates healing of deep and complex ulcers, both
ischemic and neuropathic, and reduces diabetes-related amputations.
Without any kind of disfiguring surgery, its application through
intralesional injection into the diabetic foot ulcers accelerates their
scar formation, even for deep and complex ones, also reducing the number
and spread of extirpation and debridement of dead or necrotic tissue.
In preventing recidivism, there is an evident reduction of time for scar
formation, and other complications are avoided, such as gangrene and
infections. Clinical trials of Heberprot-P in patients with diabetic foot ulcers
have shown that repeated local infiltration of this product can enhance
curing of chronic wounds safely and efficaciously. As a result, Heberprot-P
was registered in Cuba in 2006, and in 2007 was included in the
National Basic Medications List and approved for marketing. It has been
registered in 15 other countries, enabling treatment of more than
100,000 patients. (http://www.doctorcuba.com/diabetes-heberprot-p-cuba.html)
